ChemoCentryx shares surge as TAVNEOS launch gains traction

By: Quiver PriceTracker

Posted: 2 hours ago / July 2, 2026 9:24 p.m. UTC

CCXI

ChemoCentryx (CCXI) is up 15.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to stronger-than-expected early commercial momentum for TAVNEOS, the company’s newly launched treatment for ANCA-associated vasculitis. Even though quarterly revenue and earnings were weak on the surface, investors seemed to focus more on the sharp sequential sales growth, expanding prescriber adoption, and the company’s solid cash position.

Details:

First-quarter net product sales for TAVNEOS reached about $5.4 million, roughly five times the prior quarter’s level.

Management highlighted sharp increases in launch metrics, including new patient start forms, unique prescribers, and patients on therapy, suggesting improving uptake.

The company also received a $45 million milestone tied to European approval of TAVNEOS, helping lift cash and investments to about $371.8 million at quarter-end.

Pipeline updates may have added support, with the company discussing positive early data for CCX559 and plans to advance additional development programs later in 2022.

Sources:

ChemoCentryx press release, Nasdaq, Amgen press release

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive CCXI Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CCXI Hedge Fund Activity

We have seen 45 institutional investors add shares of $CCXI stock to their portfolio, and 0 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,700,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,432,000
MAGNETAR FINANCIAL LLC added 2,700,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,432,000
FORT BAKER CAPITAL MANAGEMENT LP added 2,519,848 shares (+inf%) to their portfolio in Q1 2026, for an estimated $25,601,655
SCULPTOR CAPITAL LP added 2,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $20,320,000
POLAR ASSET MANAGEMENT PARTNERS INC. added 2,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $20,320,000
ALBERTA INVESTMENT MANAGEMENT CORP added 1,500,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $15,240,000
MOORE CAPITAL MANAGEMENT, LP added 1,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $10,160,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.